Evidence map›Paper›PMID 20956980›Full record

ReviewNature reviews. Clinical oncology2010

Molecular mechanisms of metastasis in breast cancer--clinical applications.

Michal Mego, Sendurai A Mani, Massimo Cristofanilli

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Clinical oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed
10.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 231 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Modelling metastasis in a dish:Pathology oncology research : POR · 2025
    Review
  9. Review
  10. Article
  11. A Preliminary Investigation into Search and Matching for Tumor Discrimination in World Health Organization Breast Taxonomy Using Deep Networks.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2024
    Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 3 countries.

Michal MegoDepartment of Medical Oncology, Comenius University, School of Medicine, Klenova 1, Bratislava 833 10, Slovakia.
Sendurai A Mani
Massimo Cristofanilli
Comenius University Bratislava · SKFox Chase Cancer Center · USThe University of Texas MD Anderson Cancer Center · US

Funding

Human Breast Cancer Stem Cell SurrogatesR01CA138239 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CRISTOFANILLI, MASSIMO, REUBEN, JAMES MARTIN · 2008 to 2012
$2.8M
NCI NIH HHS R01 CA138239
6 · The paper itself

Abstract

The metastatic cascade is a series of biological processes that enable the movement of tumor cells from the primary site to a distant location and the establishment of a new cancer growth. Circulating tumor cells (CTCs) have a crucial role in tumor dissemination. The role of CTCs in treatment failure and disease progression can be explained by their relation to biological processes, including the epithelial-to-mesenchymal transition and 'self seeding', defined as reinfiltration of the primary tumor or established metastasis by more aggressive CTCs. CTCs are a unique and heterogeneous cell population with established prognostic and predictive value in certain clinical situations. The possibility of collecting sequential blood samples for real-time monitoring of systemic-therapy efficacy presents new possibilities to evaluate targeted therapies based on the genomic profiling of CTCs and to improve the clinical management of patients by personalized therapy. Interruption of the metastatic cascade via the targeting of CTCs might be a promising therapeutic strategy.

Indexed as

AnimalsBiomarkers, TumorBreast NeoplasmsCell MovementDisease ProgressionEpithelial-Mesenchymal TransitionFemaleHumansMammary Neoplasms, ExperimentalMatrix MetalloproteinasesMolecular Targeted TherapyNeoplasm InvasivenessNeoplasm MetastasisNeoplasm ProteinsNeoplastic Cells, CirculatingPrecision MedicineBiomarkers, TumorMatrix MetalloproteinasesNeoplasm ProteinsReceptors, ChemokineReceptors, Urokinase Plasminogen Activator

Identifiers

PMID20956980
OpenAlexW2091981858

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.